Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug17 | 0.9%NaCl Wiki | 1.00 |
| drug454 | BCG Vaccine Wiki | 0.50 |
| drug2220 | Lung ultrasound Wiki | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The COVID-19 disease has been subject to numerous publications since its emergence. Almost 20% of people suffering from COVID-19 develop severe to critical symptoms and require hospitalization, often in Intensive Care Unit (ICU). Respiratory failure is the main reason for admission in ICU of these patients. Therapeutic strategies implemented for the management of critically-ill patients may often lead to short-term muscular and functional alterations resulting in ICU-Acquired Weakness (ICUAW). These lead to long-term disabilities expressing trough dependence and quality of life impairment of survivors. The purpose of this study is to assess the quality of life, dependence and survival at one year in patients who survived from COVID-19 in ICU and are admitted in post-ICU setting for difficult weaning purpose. Ancillary studies aim to assess the course of muscle function (atrophy, structural modifications), lung function (loss of aeration) and safety of early mobilization.
Description: Quality of life will be assessed using Short Form Health Survey (SF-36) through a phone call at one year. SF-36 score range from 0 to 100, 100 indicating a better quality of life.
Measure: Mean in quality of life score at one year on the Short Form Health Survey (SF-36) Time: 1 yearDescription: Quality of life will be assessed using Short Form (36) Health Survey (SF-36) through a phone call at six months. SF-36 score range from 0 to 100, 100 indicating a better quality of life.
Measure: Mean in quality of life score at six months on the Short Form Health Survey (SF-36) Time: 6 monthsDescription: Autonomy will be assessed using Activities Daily Living (ADL) scale through a phone call at one year and six months. ADL scale range from 0 to 6, 6 indicating a better autonomy in activities daily living.
Measure: Mean in autonomy score on the Activities Daily Living (ADL) scale Time: At enrollement, 6 months and 1 yearDescription: Survival will be assessed using the death registry query and phone call for vital status recording at six months and one year. Survival rate will be expressed as a survival function using Kaplan Meier method.
Measure: Survival rate Time: 6 months and 1 yearDescription: Lung aeration will be assessed using the Lung Ultrasound Score (LUS). Patient is in semi-recumbent position (30°). Lung ultrasound will be performed in 12 thorax area: anterior, lateral and posterior, each area divided in superior and inferior area, for each hemithorax. Lung Ultrasound Score will be recorded using a convex probe with a transverse view. For each thorax area a subscore is calculated: 0 = normal profil; 1 = multiple and well-defined B-lines; 2 = confluent B-lines; 3 = lung consolidation. Sum of this subscores allows calculation of the total score out of 60. Presence of pleural thickening and subpleural consolidations will be also recorded.
Measure: Change from baseline in lung ultrasound aeration score Time: Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICUDescription: Diaphragm Ultrasound will be used to assess diaphragm thickness and excursion. Patient is in semi-recumbent position (30°). Diaphragm thickness will be performed using intercostal view with a linear probe at the zone of apposition for assessing diaphragm thickness. M-Mode will be used to measure diaphragm thickness at inspiratory time (maximal inspiration) and expiratory time (maximal expiration). Diaphragm excursion will be measured using a subcostal anterior view with convex probe. Excursion measurement is performed in M-mode as the distance between end-inspiration and end-expiration. Three measures of both DTF and excursion will performed and the better will be kept.
Measure: Change from baseline in diaphragm ultrasound thickness and excursion Time: Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICUDescription: Muscle ultrasound measurements will be performed using a linear probe with a transverse view. Thickness (cm) of vastus intermedius, rectus femori and tibialis anterior will be measured.
Measure: Mean change from baseline in ultrasound muscle thickness Time: Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICUDescription: Muscle ultrasound measurements will be performed using a linear probe with a transverse view. Cross-sectionnal area (CSA) (cm^2) of rectus femori and tibialis anterior will be measured.
Measure: Mean change from baseline in ultrasound muscle cross-sectionnal area Time: Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICUDescription: Muscle ultrasound measurements will be performed using a linear probe with a transverse view. Echogeneicity (0 to 255) of rectus femori and tibialis anterior will be measured using Image J software. Penation angle of rectus femori will be assessed. is used to measure muscle thicknesses, CSA and echogeneicity. Longitudinal view is used to measure angle of pennation.
Measure: Mean change from baseline in ultrasound muscle echogeneicity Time: Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICUDescription: Muscle ultrasound measurements will be performed using a linear probe with a longitudinal view. Penation angle (°) of rectus femori will be assessed.
Measure: Mean change from baseline in ultrasound muscle pennation Time: Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICUDescription: MRC sum score evaluates strength in three muscle groups of all four limbs. A score between 0 and 5 is assigned to each of them, which renders a maximum total score of 60.
Measure: Mean change from baseline in Medical Research Council (MRC) sum score Time: Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICUDescription: Number of adverse outcomes during early mobilization of patients will recorded at each mobilization session. Prevalence of adverse outcomes is expressed as the number of adverse outcomes divided by the number of early mobilization sessions.
Measure: Prevalence of adverse outcomes during early mobilization Time: From date of enrollement up to 30 days (date of estimated post-ICU discharge)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports